Clinical Trials Logo

Clinical Trial Summary

This is an evaluation of programs to integrate PrEP into existing services for PWUD. PrEP will be delivered according to Uganda national guidelines and data from national monitoring and evaluation forms will be leveraged to address key outcomes. Additionally, research components will be implemented to support greater understanding of PrEP use and experiences of participants engaged with the PrEP programs.


Clinical Trial Description

The first facility-based medication-assisted treatment (MAT) program (with methadone) in Kampala launched in 2020, providing opportunity to integrate pre-exposure prophylaxis(PrEP) as part of a comprehensive HIV prevention package. Additionally, a community-based needle and syringe exchange program (NSP) provides opportunity to integrate PrEP and meet priorities of PWID while building rapport between providers and end-users. With two different service models - integrating PrEP into facility-based MAT and community-based NSP - there is a great opportunity to optimize the integration of PrEP and other HIV prevention services for PWUD. By integrating PrEP into two existing programs (MAT and NSP), this study will determine uptake and persistence of PrEP use and leverage these programs to conduct costing research and budget impact analysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05040308
Study type Observational
Source University of Washington
Contact Renee Heffron, PhD, MPH
Phone 206-520-3800
Email [email protected]
Status Not yet recruiting
Phase
Start date September 2021
Completion date February 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03940521 - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Active, not recruiting NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Recruiting NCT03570918 - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy Phase 1
Recruiting NCT04022967 - ANRS 12372 MODERATO Study Phase 3
Recruiting NCT04963712 - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Phase 3
Not yet recruiting NCT04738812 - Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression Phase 3
Not yet recruiting NCT04892654 - Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch Phase 3
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting NCT03536234 - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients Phase 2
Recruiting NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4
Not yet recruiting NCT04894357 - Impact of V106I on Resistance to Doravirine
Not yet recruiting NCT04480554 - Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 Phase 2
Recruiting NCT04568239 - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Not yet recruiting NCT04311957 - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults Phase 4
Not yet recruiting NCT04311944 - Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD N/A
Not yet recruiting NCT04513496 - Telemedicine in HIV Care in Buenos Aires
Active, not recruiting NCT03998176 - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE Phase 4
Recruiting NCT04416906 - A Test and Treat Strategy in New HIV Diagnosis. Phase 3
Completed NCT04094870 - A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women Phase 4
Completed NCT03532425 - B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults Phase 4